Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Kromosi | Healthcare Services | 40.4% | 95th pct | 268 |
| Medlab 2024 | Healthcare Services | 37.4% | 94th pct | 268 |
| G.natadzis Sakhelobis S… | Healthcare Services | 21.2% | 79th pct | 268 |
| TL Medikal | Healthcare Services | 12.3% | 56th pct | 268 |
| Medi Praim | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | G.natadzis Sakhelobis S… | Kromosi | TL Medikal | Medlab 2024 | Medi Praim |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 91.5% | 73.2% | 100.0% | 64.2% | — |
| EBITDA Margin | 21.2% | 40.4% | 12.3% | 37.4% | — |
| EBITDAR | 405 | 790 | 359 | 699 | — |
| EBITDAR Margin | 21.2% | 42.8% | 20.3% | 39.6% | — |
| EBIT Margin | 14.0% | 36.2% | 6.9% | 33.0% | — |
| Net Profit Margin | -12.0% | 29.1% | 11.8% | 33.2% | — |
| Operating Expense % of Sales | 70.3% | 32.8% | 87.7% | 26.8% | — |
| Returns | |||||
| Return on Assets (ROA) | -0.6% | 24.8% | 9.1% | 44.3% | — |
| Return on Equity (ROE) | -1.2% | 1067.0% | 18.7% | 100.0% | — |
| ROIC [EBIT / Invested Capital] | 0.7% | 59.6% | 10.9% | 195.2% | — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 52.5% | 58.6% | 1.1% | 0.0% | — |
| Debt-to-Equity | 1.12x | 25.20x | 0.02x | 0.00x | — |
| Debt-to-EBITDA | 52.31x | 1.70x | 0.11x | 0.00x | — |
| Equity-to-Assets | 46.7% | 2.3% | 49.0% | 44.3% | — |
| Net Debt | 21,123 | 1,071 | -9 | -287 | — |
| Cash & Equivalents | 38 | 196 | 34 | 288 | — |
| Total Debt | 21,161 | 1,267 | 25 | 0 | — |
| Liquidity & working capital | |||||
| Current Ratio | 4.20x | 0.61x | 1.08x | 1.23x | — |
| Quick Ratio | 4.20x | 0.61x | 1.08x | 1.23x | — |
| Cash Ratio | 0.04x | 0.18x | 0.08x | 0.43x | — |
| Total Current Assets | 4,076 | 653 | 474 | 824 | — |
| Total Current Liabilities | 970 | 1,077 | 439 | 670 | — |
| Inventory | N/A | N/A | N/A | N/A | — |
| Trade Receivables | 1,942 | 247 | 109 | 340 | — |
| Trade Payables | 323 | 771 | 439 | 670 | — |
| Net Working Capital | 3,106 | -424 | 36 | 154 | — |
| Net Working Capital % of Revenue | 162.9% | -23.0% | 2.0% | 8.7% | — |
| Trade Working Capital | 1,619 | -524 | -329 | -330 | — |
| Trade Working Capital % of Revenue | 84.9% | -28.4% | -18.6% | -18.7% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | N/A | — |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | — |
| Receivables Turnover | 0.98x | 7.47x | 16.17x | 5.20x | — |
| Days Sales Outstanding (DSO) | 371.6 | 48.9 | 22.6 | 70.2 | — |
| Payables Turnover | 0.50x | 0.64x | N/A | 0.94x | — |
| Days Payable Outstanding (DPO) | 723.3 | 568.7 | N/A | 386.5 | — |
| Cash Conversion Cycle | -351.7 days | -519.9 days | 22.6 days | -316.3 days | — |
| Asset Turnover | 0.05x | 0.85x | 0.77x | 1.34x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 919 | N/A | 27 | 374 | — |
| Free Cash Flow (OCF − Capex proxy) | 1,003 | N/A | 27 | 374 | — |
| Cash Conversion (OCF / EBITDA) | 227.2% | N/A | 12.5% | 56.7% | — |
| Dividends Declared | N/A | N/A | N/A | N/A | — |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | — |